Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee

Clin Mol Hepatol. 2024;30(4):807-823. Published online July 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0333

View: 2535 Download: 272 Web of Science: 1 Crossref: 2

Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting

Xueshuai Wan, Karin Wisskirchen, Tao Jin, Lu Yang, Xiaorui Wang, Xiang’an Wu, Fang Liu, Yu Wu, Christy Ma, Yong Pang, Qi Li, Ke Zhang, Ulrike Protzer, Shunda Du

Clin Mol Hepatol. 2024;30(4):735-755. Published online May 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0058

View: 2837 Download: 301 Crossref: 2

Letter to the Editor

Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD

Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):263-265. Published online January 18, 2024

DOI: https://doi.org/10.3350/cmh.2023.0557

View: 2861 Download: 140 Web of Science: 6 Crossref: 7

Review

Recent advances in the management of hepatocellular carcinoma

Kamya Sankar, Jun Gong, Arsen Osipov, Steven A. Miles, Kambiz Kosari, Nicholas N. Nissen, Andrew E. Hendifar, Ekaterina K. Koltsova, Ju Dong Yang

Clin Mol Hepatol. 2024;30(1):1-15. Published online July 21, 2023

DOI: https://doi.org/10.3350/cmh.2023.0125

View: 8218 Download: 412 Web of Science: 22 Crossref: 21

Snapshot

Systemic therapy in advanced hepatocellular carcinoma

Joseph C. Ahn, Nguyen H. Tran, Ju Dong Yang

Clin Mol Hepatol. 2023;29(2):516-519. Published online February 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0051

View: 4734 Download: 177 Web of Science: 6 Crossref: 6

Editorial

Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences

Tian Yang, Ming-Da Wang, Xin-Fei Xu, Chao Li, Han Wu, Feng Shen

Clin Mol Hepatol. 2023;29(2):342-344. Published online March 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0106

View: 4080 Download: 80 Web of Science: 6 Crossref: 7

Review

Clinical practice guidelines and real-life practice on hepatocellular carcinoma: A the Hong Kong perspective

Rex Wan-Hin Hui, Lung-Yi Mak, Tan-To Cheung, Victor Ho-Fun Lee, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(2):217-229. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0399

View: 6744 Download: 257 Web of Science: 12 Crossref: 14

Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma

Pil Soo Sung

Clin Mol Hepatol. 2022;28(3):333-350. Published online October 19, 2021

DOI: https://doi.org/10.3350/cmh.2021.0308

View: 18084 Download: 388 Web of Science: 29 Crossref: 32

Original Article

Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study

Gyu Sang Yoo, Won-Gyun Ahn, Shin-Yeong Kim, Wonseok Kang, Changhoon Choi, Hee Chul Park

Clin Mol Hepatol. 2021;27(1):144-156. Published online December 7, 2020

DOI: https://doi.org/10.3350/cmh.2020.0095

View: 8517 Download: 308 Web of Science: 23 Crossref: 24

Editorial

Long-term prognosis and management of hepatocellular carcinoma after curative treatment

Naoshi Nishida

Clin Mol Hepatol. 2020;26(4):480-483. Published online September 21, 2020

DOI: https://doi.org/10.3350/cmh.2020.0208

View: 5911 Download: 104 Web of Science: 12 Crossref: 11

Review

Treatment options after sorafenib failure in patients with hepatocellular carcinoma

Imane El Dika, Ghassan K. Abou-Alfa

Clin Mol Hepatol. 2017;23(4):273-279. Published online November 20, 2017

DOI: https://doi.org/10.3350/cmh.2017.0108

View: 9925 Download: 237 Web of Science: 29 Crossref: 29

Original Article

Targeting TM4SF1 promotes tumor senescence enhancing CD8⁺ T cell cytotoxic function in hepatocellular carcinoma

Weifeng Zeng, Furong Liu, Yachong Liu, Ze Zhang, Haofan Hu, Shangwu Ning, Hongwei Zhang, Xiaoping Chen, Zhibin Liao, Zhanguo Zhang

Received October 28, 2024 Accepted December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0934 [Accepted]

View: 573 Download: 88

1 |

Viewed By 6146	MAFLD: How is it different from NAFLD?
Viewed By 5248	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4973	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4165	Examining the therapeutic landscape of beta-blockers in portal hypertension
Viewed By 3941	Gut microbiome and metabolome signatures in liver cirrhosis-related complications

Cited By 272	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 225	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 154	MAFLD: How is it different from NAFLD?
Cited By 79	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 76	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search